Palatin Announces Preliminary Fourth Quarter Vyleesi® Net Product Revenue Increased 225% Over Prior Quarter
Jul 26, 2022, 07:30 ET Gross product sales increased 75% andPrescriptions dispensed increased 45%, over prior quarter CRANBURY, N.J., July 26, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced preliminary fourth quarter …